PL2641596T3 - Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby - Google Patents

Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby

Info

Publication number
PL2641596T3
PL2641596T3 PL13170128T PL13170128T PL2641596T3 PL 2641596 T3 PL2641596 T3 PL 2641596T3 PL 13170128 T PL13170128 T PL 13170128T PL 13170128 T PL13170128 T PL 13170128T PL 2641596 T3 PL2641596 T3 PL 2641596T3
Authority
PL
Poland
Prior art keywords
diphenylprop
derivatives
treating liver
liver disorders
disorders
Prior art date
Application number
PL13170128T
Other languages
English (en)
Inventor
Raphaël Darteil
Rémy HANF
Dean Hum
Ingrid Dufour
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of PL2641596T3 publication Critical patent/PL2641596T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL13170128T 2009-11-26 2010-11-26 Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby PL2641596T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09306146 2009-11-26
EP13170128.6A EP2641596B1 (en) 2009-11-26 2010-11-26 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
EP10787363.0A EP2504005B1 (en) 2009-11-26 2010-11-26 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

Publications (1)

Publication Number Publication Date
PL2641596T3 true PL2641596T3 (pl) 2018-10-31

Family

ID=43587223

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13170128T PL2641596T3 (pl) 2009-11-26 2010-11-26 Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
PL10787363T PL2504005T3 (pl) 2009-11-26 2010-11-26 Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10787363T PL2504005T3 (pl) 2009-11-26 2010-11-26 Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby

Country Status (24)

Country Link
US (2) US8772342B2 (pl)
EP (2) EP2641596B1 (pl)
JP (4) JP5833016B2 (pl)
KR (2) KR101865677B1 (pl)
CN (2) CN104434891B (pl)
AU (1) AU2010323066B2 (pl)
BR (1) BR112012012815B8 (pl)
CA (1) CA2781451C (pl)
CY (2) CY1116548T1 (pl)
DK (2) DK2504005T3 (pl)
EA (1) EA020849B1 (pl)
ES (2) ES2441665T3 (pl)
HU (1) HUE039731T2 (pl)
IL (2) IL219914A (pl)
LT (1) LT2641596T (pl)
MX (1) MX2012006062A (pl)
NZ (1) NZ600439A (pl)
PH (1) PH12012501054A1 (pl)
PL (2) PL2641596T3 (pl)
PT (2) PT2504005E (pl)
SI (2) SI2504005T1 (pl)
TR (1) TR201810393T4 (pl)
WO (1) WO2011064350A1 (pl)
ZA (1) ZA201204658B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2441665T3 (es) 2009-11-26 2014-02-05 Genfit Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
EP3009136A1 (en) 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
DK2948137T3 (en) * 2013-01-18 2019-01-07 Genfit METHODS OF TREATING FIBROSE AND CANCER TYPES
UA114360C2 (uk) 2013-04-22 2017-05-25 Каділа Хелткере Лімітед Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (pl) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (pl) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
CA2951337C (en) 2014-06-13 2022-08-23 Inventiva Ppar compounds for use in the treatment of fibrotic diseases
ES2905872T3 (es) 2015-02-06 2022-04-12 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia combinada
MX2018003077A (es) * 2015-09-14 2018-05-28 Genfit Metodos para diagnosticar y evaluar esteatohepatitis no alcoholica.
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
US10442761B2 (en) 2016-02-16 2019-10-15 Concert Pharmaceuticals, Inc. Deuterated GFT-505
US11331292B2 (en) 2016-03-31 2022-05-17 Genfit Methods of treatment of cholestatic diseases
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
PL3435996T3 (pl) * 2016-03-31 2025-07-28 Genfit Elafibranor do zastosowania w leczeniu pierwotnego zapalenia dróg żółciowych
FR3056908B1 (fr) 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
FR3056909B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree
EP3551180B1 (en) 2016-12-09 2021-09-29 Cadila Healthcare Limited Treatment for primary biliary cholangitis
JP2020505355A (ja) * 2017-01-22 2020-02-20 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド Ｇｆｔ−５０５の結晶形及びその製造方法並びに用途
CA3051977A1 (en) * 2017-02-24 2018-08-30 Genfit Pharmaceutical compositions for combination therapy
CA3058542A1 (en) 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
WO2019105234A1 (zh) 2017-11-30 2019-06-06 四川科伦博泰生物医药股份有限公司 芳香族化合物及其药物组合物和用途
TWI918595B (zh) 2018-08-03 2026-03-21 法商Ｇｅｎｆｉｔ公司 艾拉菲諾鹽
MA53188A1 (fr) * 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques
RU2702003C1 (ru) * 2019-03-18 2019-10-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный химико-фармацевтический университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России) Антистеатозное средство
WO2020208205A1 (en) 2019-04-10 2020-10-15 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
CN110143902B (zh) * 2019-06-12 2021-06-04 天津科技大学 含硒查尔酮衍生物Compound 1和合成方法及在抗非酒精性脂肪肝炎药物中的应用
CN110143890B (zh) * 2019-06-12 2020-12-22 天津科技大学 一种查尔酮衍生物和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用
JP2023513712A (ja) 2020-02-10 2023-04-03 ジェンフィット エラフィブラノールの多形体
CN115884765A (zh) 2020-08-26 2023-03-31 基恩菲特公司 用于治疗原发性胆汁性胆管炎的组合物和方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04202129A (ja) 1990-11-30 1992-07-22 Terumo Corp 肝障害治療薬
JPH09501920A (ja) 1993-08-19 1997-02-25 ワーナー−ランバート・コンパニー 非ペプチドエンドセリンアンタゴニスト▲ｉ▼
EP1242352A2 (en) 1999-12-23 2002-09-25 University Of Georgia Research Foundation, Inc. Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
WO2001098291A2 (en) * 2000-06-20 2001-12-27 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
KR100567125B1 (ko) 2001-11-01 2006-03-31 주식회사 안지오랩 칼콘 또는 이의 유도체를 함유하는 매트릭스메탈로프로테아제 활성 억제용 약학 조성물
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2841784B1 (fr) * 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
BRPI0506718A (pt) * 2004-01-08 2007-05-02 Genfit compostos, processo de preparação dos mesmos, e, composição farmacêutica ou cosmética
JP4689331B2 (ja) 2005-04-19 2011-05-25 三菱電機株式会社 撮像装置
FR2902789A1 (fr) * 2006-06-21 2007-12-28 Genfit Sa Derives de 1,3-diphenylpropane substitues, preparations et utilisations
DE102006062264A1 (de) * 2006-12-22 2008-06-26 Joh. Barth & Sohn Gmbh & Co. Kg Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
ES2441665T3 (es) * 2009-11-26 2014-02-05 Genfit Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos

Also Published As

Publication number Publication date
US8772342B2 (en) 2014-07-08
LT2641596T (lt) 2018-08-10
CN104434891B (zh) 2018-03-30
WO2011064350A1 (en) 2011-06-03
ES2441665T3 (es) 2014-02-05
KR101962209B1 (ko) 2019-03-26
JP2018070642A (ja) 2018-05-10
DK2641596T3 (en) 2018-08-06
CN102647982B (zh) 2014-10-15
EA201290389A8 (ru) 2014-05-30
TR201810393T4 (tr) 2018-08-27
DK2504005T3 (da) 2014-01-13
JP2020073468A (ja) 2020-05-14
EP2641596A1 (en) 2013-09-25
EA020849B1 (ru) 2015-02-27
KR101865677B1 (ko) 2018-07-16
CA2781451C (en) 2019-04-16
PH12012501054A1 (en) 2014-09-05
PL2504005T3 (pl) 2014-03-31
MX2012006062A (es) 2012-06-28
HK1175716A1 (en) 2013-07-12
ZA201204658B (en) 2013-05-29
US20120252725A1 (en) 2012-10-04
IL241791A0 (en) 2015-11-30
CY1120444T1 (el) 2019-07-10
US8895619B2 (en) 2014-11-25
JP5833016B2 (ja) 2015-12-16
PT2504005E (pt) 2014-01-10
KR20180031825A (ko) 2018-03-28
CY1116548T1 (el) 2017-03-15
BR112012012815B1 (pt) 2021-02-02
JP6594400B2 (ja) 2019-10-23
IL219914A0 (en) 2012-07-31
KR20120101472A (ko) 2012-09-13
HUE039731T2 (hu) 2019-01-28
SI2504005T1 (sl) 2014-04-30
AU2010323066A1 (en) 2012-06-07
JP2016074670A (ja) 2016-05-12
AU2010323066B2 (en) 2014-12-11
BR112012012815A8 (pt) 2018-02-27
IL219914A (en) 2015-10-29
BR112012012815A2 (pt) 2017-12-12
PT2641596T (pt) 2018-07-31
EP2641596B1 (en) 2018-05-02
BR112012012815B8 (pt) 2021-05-25
EP2504005A1 (en) 2012-10-03
US20140309165A1 (en) 2014-10-16
JP2013512228A (ja) 2013-04-11
EA201290389A1 (ru) 2013-01-30
CN102647982A (zh) 2012-08-22
ES2681794T3 (es) 2018-09-17
CN104434891A (zh) 2015-03-25
SI2641596T1 (sl) 2018-09-28
NZ600439A (en) 2014-06-27
CA2781451A1 (en) 2011-06-03
EP2504005B1 (en) 2013-11-06

Similar Documents

Publication Publication Date Title
ZA201204658B (en) Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
ZA201007127B (en) Carboxamide compounds for the treatment of metabolic disorders
SI2229369T1 (sl) Derivati 6,7-dialkoksi kinazolina, uporabni za zdravljenje motenj, povezanih z rakom
ZA201107446B (en) Compounds for the treatment of metabolic disorders
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
GB0904285D0 (en) Compounds for the treatment of metabolic disorders
GB0904284D0 (en) Compounds for the treatment of metabolic disorders
IL210290A0 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
ZA201204391B (en) Compounds for the treatment of neurologic disorders
IL209417A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
EP2387402A4 (en) METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS WITH 2,4-PYRIMIDINIAMIN COMPOUNDS
IL207906A0 (en) Treatment for ocular-related disorders
EP2387565A4 (en) 2,4-PYRIMIDINDIAMIN COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES
PT2278962E (pt) Métodos para o tratamento de desordens dermatológicas
GB2476644B (en) 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis
EP2240024A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP2349299A4 (en) COMPOSITION FOR THE TREATMENT OF HYPERTENSION
GB0904288D0 (en) Compounds for the treatment of metabolic disorders
GB0904289D0 (en) Compounds for the treatment of metabolic disorders
GB0904290D0 (en) Compounds for the treatment of metabolic disorders
GB0904286D0 (en) Compounds for the treatment of metabolic disorders
GB0724947D0 (en) Composition for the treatment of psychiatric disorders
AU2009905647A0 (en) Combination for treating metabolic disorders
HK1163684A (en) Compounds for the treatment of metabolic disorders
HK1163686A (en) Compounds for the treatment of metabolic disorders